Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics

被引：0
|
作者：
Jörg Mahlich
Kerstin Olbrich
Adrian Wilk
Antonie Wimmer
Claus Wolff-Menzler
机构：
[1] Health Economics and Outcomes Research,Düsseldorf Institute of Competition Economics (DICE)
[2] Janssen,Team Gesundheit
[3] Pharmaceutical Companies of Johnson & Johnson,Department of Psychiatry and Psychotherapy
[4] University of Düsseldorf,undefined
[5] Gesellschaft für Gesundheitsmanagement mbH,undefined
[6] Medical Affairs,undefined
[7] Janssen,undefined
[8] Pharmaceutical Companies of Johnson & Johnson,undefined
[9] University Medical Center Göttingen,undefined
[10] Georg-August-University,undefined
来源：
Clinical Drug Investigation | 2021年 / 41卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：99 / 113
页数：14
相关论文
共 50 条
  • [1] Time to Treatment Discontinuation in German Patients with Schizophrenia: Long-Acting Injectables versus Oral Antipsychotics
    Mahlich, Joerg
    Olbrich, Kerstin
    Wilk, Adrian
    Wimmer, Antonie
    Wolff-Menzler, Claus
    CLINICAL DRUG INVESTIGATION, 2021, 41 (01) : 99 - 113
  • [2] Treatment discontinuation of long-acting injectables or oral atypical antipsychotics among Medicaid recipients with schizophrenia
    Song, Xue
    El Khoury, Antoine C.
    Brouillette, Matthew
    Smith, David
    Joshi, Kruti
    JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) : 1105 - 1112
  • [3] Systematic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia
    Lafeuille, Marie-Helene
    Dean, Jason
    Carter, Valerie
    Duh, Mei Sheng
    Fastenau, John
    Dirani, Riad
    Lefebvre, Patrick
    CURRENT MEDICAL RESEARCH AND OPINION, 2014, 30 (08) : 1643 - 1655
  • [4] Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
    Thiem, Helena
    Folkerts, Here
    Voelkel, Lukas
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2020, 25 (03): : 170 - 178
  • [5] Medication adherence and discontinuation of long-acting injectable versus oral antipsychotics in patients with schizophrenia or bipolar disorder
    Greene, Mallik
    Yan, Tingjian
    Chang, Eunice
    Hartry, Ann
    Touya, Maelys
    Broder, Michael S.
    JOURNAL OF MEDICAL ECONOMICS, 2018, 21 (02) : 127 - 134
  • [6] Long-acting injectable versus oral antipsychotics for schizophrenia
    Munkholm, Klaus
    LANCET PSYCHIATRY, 2021, 8 (07): : 566 - 567
  • [7] Hospital Readmission Rates Among Patients With Schizophrenia Treated With Long-Acting Injectables or Oral Antipsychotics
    MacEwan, Joanna P.
    Kamat, Siddhesh A.
    Duffy, Ruth A.
    Seabury, Seth
    Chou, Jacquelyn W.
    Legacy, Susan N.
    Hartry, Ann
    Eramo, Anna
    Karson, Craig
    PSYCHIATRIC SERVICES, 2016, 67 (11) : 1183 - 1188
  • [8] SYSTEMATIC REVIEW OF LONG-ACTING INJECTABLES (LAI) VERSUS ORAL ATYPICAL ANTIPSYCHOTICS (OA) ON HOSPITALIZATION IN SCHIZOPHRENIA
    Lafeuille, M. H.
    Cloutier, M.
    Fortier, J.
    Duh, M. S.
    Fastenau, J.
    Dirani, R.
    Lefebvre, P.
    VALUE IN HEALTH, 2014, 17 (03) : A210 - A210
  • [9] Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
    Lin, Ching-Hua
    Chen, Feng-Chua
    Chan, Hung-Yu
    Hsu, Chun-Chi
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2019, 22 (09): : 541 - 547
  • [10] Long-acting injectable versus oral antipsychotics for schizophrenia reply
    Kishimoto, Taishiro
    Hagi, Katsuhiko
    Kurokawa, Shunya
    Kane, John M.
    Correll, Christoph U.
    LANCET PSYCHIATRY, 2021, 8 (07): : 567 - 567
12345